MedTrace Logo

Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

NCT03708848 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2019-12-10

No results posted yet for this study

Summary

Increasing drug resistance presents a significant challenge to the efficacies of common empiric eradication regimens for Helicobacter pylori treatment in the mainland of China. Tailored therapy may be the best choice to achieve good efficacy, especially in patients with penicillin allergy. Few studies had evaluated the patients with penicillin allergy.This study is designed to evaluate the efficacy and safety of antibiotic sensitivity-based tailored therapy for Helicobacter pylori treatment in the patients with penicillin allergy.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Esomeprazole

Proton pump inhibitor

DRUG

Bismuth Potassium Citrate

Gastric mucosal protective drug with anti-H. pylori effect

DRUG

Clarithromycin

antibiotic for H. pylori eradication

DRUG

Metronidazole

antibiotic for H. pylori eradication

DRUG

Levofloxacin

antibiotic for H. pylori eradication

DRUG

Tetracycline

antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Hong Lu, M.D.,Ph.D. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-05
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03708848 on ClinicalTrials.gov